Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors

Cancer

Volumn 82, Issue 3, 1998, Pages 567-575

  Bosch, Francesc ^a   López Guillermo, Armando ^a   Campo, Elias ^a   Ribera, Josep M ^b   Conde, Eulogio ^c   Piris, Miguel Angel ^d   Vallespí, Teresa ^e   Woessner, Soledad ^f   Montserrat, Emilio ^a,g  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f L'Alianca Central Hospital   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Cyclin D1; Lymphoma; Mantle cell; Prognosis; Therapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; SURVIVAL RATE;

EID: 2642618607     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z     Document Type: Article

References (40)

1. Berard CW, Dorfman RF. Histopathology of malignant lymphomas. Clin Haematol 1974;3:39-43.
2. Lennert K. Centrocytic lymphoma. In: Lennert K, editor. Histopathology of non-Hodgkin's lymphoma (based on the Kiel classification). New York, NY: Springer-Verlag, 1981:57-62.
3. Non-Hodgkin's lymphoma pathologic classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a Working Formulation for clinical usage. Cancer 1982;49: 2122-35.
4. Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma. A follicular variant of intermediate lymphocytic lymphoma. Cancer 1982;49:1429-38.
5. Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K, et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992;16:637-40.
6. Lardelli P, Bookman MA, Sundeen J, Longo DL, Jaffe ES. Lymphocytic lymphoma of intermediate differentiation: morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 1990;14:752-63.
7. Weisenburger DD, Armitage JO. Mantle cell lymphoma-an entity comes of age. Blood 1996;87:4483-94.
8. Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257-62.
9. Pittaluga S, Wlodarska I, Stul MS, Thomas J, Verhoef G, Cassiman JJ, et al. Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopathology 1995;26:17-24.
10. Weisenburger DD, Sanger WG, Armitage JO, Purtilo DT. Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings. Blood 1987;69:1617-25.
11. Vandenberghe E, De Wolf-Peeters C, Wlodarska I, Stul M, Louwagie A, Verhoef G, et al. Chromosome 11q rearrangements in B non-Hodgkin's lymphoma. Br J Haematol 1992;81:212-7.
12. Motokura T, Bloom T, Kim HG, Júppner H, Ruderman JV, Kronenberg HM, et al. A novel cyclin encoded BCL1-linked candidate oncogene. Nature 1991;350:512-5.
13. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL, et al. PRAD1, a candidate bell oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991;88:9638-42.
14. Dowdy SF, Hinds PW, Louie K, Redd SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993;73:499-11.
15. Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N, et al. PRAD1/Cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84:2726-32.
16. Rimokh R, Berger F, Delsol G, Charrin C, Bertheas MF, Ffrench M, et al. Rearrangement and overexpression of the bcl-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in the t(11q13)-bearing leukemias. Blood 1993;81:3063-7.
17. Zucca E, Stein H, Coiffier B. European Lymphoma Task Force (ELTF): report of the Workshop on mantle cell lymphoma (MCL). Ann Oncol 1994;5:507-11.
18. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
19. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995;85:1075-82.
20. Norton AJ, Matthews J, Pappa V, Shamash J, Love S, Rohatiner AZ, et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995;6:249-56.
21. Berger F, Felman P, Sonet A, Salles G, Bastion Y, Bryon PA, et al. Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. Blood 1994;83:2829-35.
22. Velders GA, Muin-Nelemans JC, De Boer CJ, Hermans J, Noordijk EM, Schuuring E, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996;14:1269-74.
23. Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997;15:1664-71.
24. Pinyol M, Campo E, Nadal A, Terol MJ, Jares P, Nayach I, et al. Detection of the bcl-1 rearrangement at the major translocation cluster in frozen and paraffin-embedded tissues of mantle cell lymphomas by polymerase chain reaction. Am J Clin Pathol 1996;105:532-7.
25. The International non-Hodgkin's lymphoma prognostic factors project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
26. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
27. 2/E in the log-rank test for survival data or tumor incidence data. Biometrics 1973;29:759-84.
28. Dixon WJ, Brown MB, Engelman L, Hill MA, Jennrich RI. Dixon WJ, editors. BMDP statistical software. Berkeley, CA: University of California Press, 1988:719-43.
29. Williams ME, Swerdlow SH, Rosenberg CL, Arnold A. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 1992;52:5541s-4s.
30. Zucca E, Fontana S, Roggero E, Pedrinis E, Pampallona S, Cavalli F. Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution. Leuk Lymphoma 1996;13: 105-10.
31. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbeke M, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995;13:2819-26.
32. Montserrat E, Bosch F, Lopez-Guillermo A, Graus F, Terol MJ, Campo E, et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996;14:941-4.
33. Garcia-Conde I, Cabanillas F. Mantle cell lymphoma: a new lymphoproliferative entity with definite histopathological patterns, clinical characteristics and prognostic factors, and an investigational therapeutic approach. Ann Oncol 1995;6: 305-6.
34. Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernandez PL, et al. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with Cyclin D1 (PRAD1/ CCND1) mRNA levels and proliferative activity. Am J Pathol 1996;148:1591-600.
35. Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, et al p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996;87:3351-9.
36. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty W, Schluger A, et al p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11; 14)(q13;q32). Blood 1995;86:2892-9.
37. Pinyol M, Hernandez L, Cazorla M, Balbin M, Jares P, Fernandez PL, et al. Deletions and loss of expression of p16/ INK4a and p21/Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997;89:272-80.
38. Meusers P, Engelhard M, Bartels H, Binder T, Fülle HH, Görg K, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma. Anthracycline does not improve the prognosis. Hematol Oncol 1988;7:365-80.
39. Stewart DA, Vose JM, Weisenburger DD, Anderson JR, Ruby EI, Bast MA, et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995;6:263-6.
40. Romaguera J, Khouri I, Kantarjian H, Terol-Casterá MJ, Rodriguez MA, Hagemeister FB, et al. HCVAD/MTX-ARAC: a new effective regimen for diffuse and nodular mantle lymphoma (MCL). Blood 1996;88:568a.